Resistance to MEK Inhibitors: Should We Co-Target Upstream?

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Signaling.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Resistance to MEK Inhibitors: Should We Co-Target Upstream?

  Message Subject (Your Name) has forwarded a page to you from Science Signaling

  Message Body (Your Name) thought you would like to see this page from the Science Signaling web site.

  Your Personal Message

  CAPTCHA

  This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

  Send Message
• Download Powerpoint
• Print
• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS ID

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  Resistance to MEK Inhibitors: Should We Co-Target Upstream?

  By Poulikos I. Poulikakos, David B. Solit

  Science Signaling29 Mar 2011 : pe16

  Amplification of an upstream kinase in a three-kinase module confers resistance to cancer drugs that target a downstream kinase.

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Resistance to MEK Inhibitors: Should We Co-Target Upstream?

  By Poulikos I. Poulikakos, David B. Solit

  Science Signaling29 Mar 2011 : pe16

  Amplification of an upstream kinase in a three-kinase module confers resistance to cancer drugs that target a downstream kinase.

  Share This Article: Copy